Notícias e Atividades da Clarity Pharmaceuticals

Clarity Pharmaceuticals é uma empresa listada sob o símbolo CU6 (AU).

Veja o organograma con seus 24 executivos principais

Biografias mais buscadas da Clarity Pharmaceuticals

• Michelle Parker, Chief Executive Officer
• Thomas Ramdahl, Director
• Chris Roberts, Non-Executive Director

Recentes movimentos de executivos em Clarity Pharmaceuticals

• Colin Biggin antes Excecutive Director, agora é Chief Operating Officer  (Notícia publicada em 12 de abril de 2026).

Criar um alerta
para seguir os movimentos de executivos da Clarity Pharmaceuticals.

Clarity Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Clarity Pharmaceuticals

• Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity’s COBRA study selected as a Top-Rated Oral Presentation at prestigious industry Annual Meeting - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity promotes Michelle Parker to CEO - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Copper-67 SAR-bisPSMA updates - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity launches $121 million fully underwritten equity raising - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity successfully completes Placement and Institutional Entitlement Offer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• SECuRE update: First participant treated in the last cohort of dose escalation - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity’s theranostic prostate cancer trial advances to multi-dose phase - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• View more press releases Close

Redes sociais sobre Clarity Pharmaceuticals

• Clarity Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Clarity Pharmaceuticals na LinkedIn, X (Twitter) e YouTube